论文部分内容阅读
目的 :观察地塞米松缓释剂前房内植入对外伤性白内障人工晶状体植入术后炎症反应、后囊混浊的预防和治疗效果。方法 :将近 2年来在我院就诊的 2 2例外伤性白内障患者随机分为两组 ,一组 (1 0例 )行白内障摘除人工晶状体植入后 ,前房内植入地塞米松缓释剂 (植入组 ) ,另一组 (1 2例 )为对照组只做白内障摘除人工晶状体植入。观察两组术后视力、前房炎症以及后发障的发生率。结果 :术后视力 :植入组 :1 0者 6例 ,0 6者 2例 ,0 3者 3例 ;对照组 :1 0者 4例 ,0 6者 2例 ,0 3者 4例 ,0 1者 2例。术后前房炎症反应和后囊混浊发生情况 :植入组明显低于对照组 ,差异有显著性 (P <0 0 5)。结论 :前房内植入地塞米松缓释剂可有效地减轻外伤性白内障人工晶状体植入术后炎症反应 ,预防后发障的发生。是一种安全有效的给药途径。
OBJECTIVE: To observe the effect of dexamethasone sustained-release in the anterior chamber on inflammatory reaction and posterior capsular opacification after traumatic cataract surgery. Methods: Twenty-two cases of traumatic cataract who were treated in our hospital in recent 2 years were randomly divided into two groups. One group (10 cases) underwent cataract extraction and posterior chamber intraocular lens implantation. Anterior chamber implantation of dexamethasone sustained- (Implantation group) and the other group (12 patients) as the control group only with cataract extraction and intraocular lens implantation. The postoperative visual acuity, inflammation of the anterior chamber and the incidence of post-stroke were observed. Results: Postoperative visual acuity: the implantation group: 10 cases in 6 cases, 0 6 cases in 2 cases, 0 3 cases in 3 cases; control group: 10 cases in 4 cases, 0 6 cases in 2 cases, 0 3 cases in 4 cases, 0 1 in 2 cases. Postoperative anterior chamber inflammatory response and posterior capsular opacification: implantation group was significantly lower than the control group, the difference was significant (P <0 05). Conclusion: Anterior chamber implantation of dexamethasone sustained-release agent can effectively reduce post-traumatic cataract intraocular lens implantation inflammatory reaction and prevent the occurrence of post-cataract. Is a safe and effective route of administration.